Company Active LTD

Company profile

Smi Drug Discovery Limited

UK company 11175710, incorporated on 29 January 2018.

SMi Drug Discovery

Smi Drug Discovery Limited is a UK company with status Active founded in 2018 based in East of England.

Company number
11175710
Incorporated
29 Jan 2018
Companies House status
Active

Company identity

Founded / incorporated
29 January 2018

Company number 11175710

Verify at Companies House
Legal name
SMI DRUG DISCOVERY LIMITED
Company type
Private Limited Company
Region
East of England
Registered address
LIBRA BUILDING
339 EXNING ROAD
NEWMARKET
SUFFOLK
UNITED KINGDOM
CB8 0AT
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

7 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

20 Jan
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

29 Jul
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUzNTc1NjQ4N2FkaXF6a2N4

Published 29 Jul 2026 09:46

07 Jul
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzUzMDk4Mjk2MGFkaXF6a2N4

Published 07 Jul 2026 11:12

06 Jan
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

29 Jan
2018

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2021
Funded years
2021, 2022
Age at first award
3 years

Projects

2022 Collaborative R&D Lead participant

An automated optical device that uses direct visualisation of single molecules for routine screening of cancer biomarkers.

1 Dec 2022 to 31 Jul 2024

Awarded
£174,920
Total cost £249,885

SMi is developing a new technology that analyses patient samples by directly visualising the single molecules that are responsible for different diseases. Using this approach SMi applies a patient sample to the surface of its consumable diagnostic chips and places these chips inside a specialised, benchtop, super-resolution microscope that can scan a larg...

2021 Collaborative R&D Lead participant

A novel automated optical device that rapidly screens large numbers of patient samples for past and present COVID-19 infection

1 Aug 2021 to 31 Jan 2023

Awarded
£1,335,868
Total cost £1,908,383

SMi Drug Discovery, a developer of optical devices capable of unprecedented levels of resolution, has designed an automated diagnostic device that will enable the detection of both past and present COVID-19 infections. Unlike other tests, SMi's technology directly observes single molecules to provide irrefutable evidence of their existence. The device pro...

Product types

Collaborative R&D